Product
Pembrolizumab in Combination with Plinabulin and Docetaxel
1 clinical trial
1 indication
Indication
Non Small Cell Lung Cancer MetastaticClinical trial
A Phase 2 Study of Pembrolizumab in Combination With Plinabulin and Docetaxel in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer and Progressive Disease (PD) After Immunotherapy (Anti-PD-1/PD-L1 Inhibitor) Alone or in Combination With Platinum-doublet Chemotherapy (KeyPemls-004)Status: Recruiting, Estimated PCD: 2024-12-31